Outlook Therapeutics, Inc. established the wholesale acquisition cost for LYTENAVA™ in the United States of $485 per vial

Outlook Therapeutics (OTLK) appointed Greg DiPasquale as Chief Commercial Officer to lead U.S. commercialization of LYTENAVA, expected to launch by end of 2026 for wet AMD patients. According to the company, this is a step toward commercialization.

Outlook Therapeutics (OTLK) announced Kevin Lundquist as its new CFO, emphasizing his role in the upcoming U.S. launch of FDA-approved LYTENAVA for wet AMD. The company is transitioning from development to commercialization, though specific launch timing and sales metrics are not yet disclosed.

Outlook Therapeutics (OTLK) presented its commercial strategy for LYTENAVA, its newly FDA-approved eye drug, at the H.C. Wainwright conference. The company aims for a focused launch targeting practices dissatisfied with repackaged bevacizumab, with pricing under $500 per dose. Success hinges on payer access and a permanent billing code expected in 2027. OTLK's stock has fallen 58% year-to-date but rebounded 57% in six months, with a market cap of $161M. The company remains unprofitable, with neg

Outlook Therapeutics (OTLK) shares surged 140% after the FDA granted its appeal for Lytenava, an eye disease drug. The company plans to resubmit its BLA in 2026. Directors bought shares, and the company raised $5M in a direct offering. OTLK stock is up sharply this week but down 54% over the past year.

U.S. stock futures rose early Monday due to reports of a U.S.-Iran ceasefire, easing fears and leading to a crude oil price drop. Key companies like Nvidia (NVDA), Oracle (ORCL), and Outlook Therapeutics (OTLK) saw premarket movements. The week ahead includes major tech earnings and Fed decisions.

Outlook Therapeutics (OTLK) shares rose 21% after resubmitting its FDA application for Lytenava to treat nAMD, following a successful appeal. The FDA previously denied approval but now agrees no additional trials are needed. A decision is expected within 60 days. Lytenava, if approved, would be the first FDA-approved ophthalmic formulation of bevacizumab. The stock has fallen 50% over the past year.